JERSEY CITY, N.J., July 23, 2013 /PRNewswire/ -- Exalenz Bioscience (TASE: EXEN), developer of advanced diagnostic systems that use a patient's breath to detect and help manage gastrointestinal and liver conditions, today named Gavin Doree the company's new vice president of sales.
Today's news follows the world market launch of the BreathID® Hp, a second generation device, that using the real-time, continuous breath of a patient, detects the presence of the H. pylori bacteria, the cause of various illnesses including peptic ulcers and is associated with gastric cancer. It also follows Exalenz's establishment of a new direct sales organization, which Doree has been hand-selected to lead in providing superior customer service and support.
"We are very excited that Gavin has joined the Exalenz family. He has a strong, successful history in the GI field as well as a great and impressive track record in various leadership roles. We are certain he is the right person to lead the new direct sales organization established in the U.S. and its part in the continued roll-out of the new BreathID Hp," said Exalenz CEO Lawrence Cohen.
For the past two years, Mr. Doree has served as the national director and the director of strategic accounts at Medivators Inc. (formerly Minntech Corporation), a leader in developing, manufacturing, and marketing medical devices, specializing in patient safety, infection prevention and asset management technologies. As the national director of sales for Medivators in 2012-13, Mr. Doree managed sales of $35M US and was part of a leadership responsible for $157M US sales. He is also the former West Region director of sales at Byrne Medical, Inc., where, in 2009 he grew business by 36% for a total sales figure of more than $7 million. He repeated this success in 2010, when he further grew business by 23% for a total sales figure of more than $13 million. Mr. Doree also had strong success as territory manager at Parks Medical Corporation, where he helped the company to increase sales to the millions. Before pursuing a career in the medical field, Mr. Doree worked as an educator and athletic director in the State of Washington.
"This is an exciting time in the evolution of Exalenz. The company listened to its customers and developed a new generation system and a new market strategy that we expect will fill a large unmet market need. It took three years to develop the BreathID Hp, which unlike the original product, is EMR compatible and small enough to fit on a desk or countertop. Like the original, it too detects the H. pylori bacteria in the quickest, most highly accurate test on the market today. It's the best of all worlds," said Mr. Doree. "In terms of strategy, I'm keen to lead the new and highly professional direct sales team and to provide our clients with the very best customized, readily available, top quality service."
Mr. Doree is the recipient of various awards including the Byrne Medical, Inc. Regional Director of the Year, three years running (2009-2011) and Sales Representative of the Year at Parks Medical in 2007 and 2008. He holds a BA in political science from the University of Washington and a masters in teaching from Whitworth University.
About Exalenz Bioscience
Exalenz Bioscience develops advanced diagnostic systems that use the real-time, continuous flow of a patient's breath to diagnose and help manage digestive system and liver conditions. The company's second generation pipeline product, the BreathID Hp, detects the presence of the H. pylori bacteria, the cause of various illnesses. It is also EMR compatible and compact in size. To date, blood tests or stool samples have been used to detect the same, in uncomfortable procedures which have limited accuracy and which require days to secure results. BreathID Hp, which is both patient and technician friendly, provides results in around 10-15 minutes, and is clinically proven to be 99% accurate. Unlike the competition, the BreathID takes continuous samples of breath and operation is as simple as pushing one button. The BreathID Hp system is FDA cleared and has a CE mark.
This news release may contain "forward-looking statements." Statements in this press release, which are not purely historical, are forward-looking statements including statements concerning the Company's business outlook or future economic performance, anticipated revenues, expenses or other financial items, plans and objectives related thereto, and assumptions or expectations relating to any future events, conditions, performance or other matters. Forward-looking statements are subject to risks, uncertainties and factors including, but not limited to, changing customer demands, changing regulatory requirements, customer acceptance of the Company's products, the impact of competitive products and pricing, dependence on existing management, that technology may not function as expected and general economic conditions. The Company assumes no obligation to update the information in this release.
|SOURCE Exalenz Bioscience|
Copyright©2012 PR Newswire.
All rights reserved